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The AACR Cancer Progress Report (2011) shows that in
the USA from 1990 to 2007, death rates from all cancers
dropped to 22% in men and 14% in women. More than
68% of adults live five years or more after diagnosis, up from
50% in 1975. For all paediatric cancers, the five-year survival
rate is 80%, compared with 52% in 1975. However, the poor
survival rates from most deadly cancers, pancreatic, ovarian
and glioblastoma multiforme (GBM), have not changed to
this date.
Despite many technological and clinical advances, cancer
death rates are still high. Patient death arises from the
failure to detect primary tumors before they spread their
micrometastases around the body, as in pancreatic and
ovarian cancers, the inability to control primary tumors, as
in GBM, or the inability to eliminate micrometastases before
they form new lesions. Disseminated disease is the primary
cause of cancer death.
On top of this is the rapidly developing cost of the
management of cancer. Cancer causes the highest economic
loss of all of the 15 leading causes of death worldwide.
The World Health Organisation (WHO) notes that the
economic toll from cancer is nearly 20% higher than heart
disease, the second leading cause of economic loss ($895
billion and $753 billion, resp.). Health budgets in developed
countries are continually expanding and constrained by
limited resources. But cost/benefit analyses to determine
whether the increased cost of treatment achieves improved
outcomes remain unknown.
Approaches to understanding the causes and treatment
of cancer are numerous, involving chemistry, physics, biol-
ogy, genetics, medicine, pharmacology, and experiments
based on in vivo or in vitro setups, using animal models
and/or human trials. Among the plethora of experimental
and research activities, mathematical models of cancer
growth, behaviour, and response of tumors to agents like
chemotherapy and radiotherapy have been the subject of
intensive research and development since the middle of
the last century. Just like all other cancer research, cancer
modeling requires a multidisciplinary approach, involving
physicists, mathematicians, molecular biologists, medical
specialists, and many others. At present, the rapid growth of
computational power allows us to build complex mathemati-
cal models that can investigate diﬀerent aspects of the disease
and can be used to investigate the role of complex tumor
behaviour and its response to various therapeutic protocols.
In general, modeling methods can be divided into analyt-
ical methods and stochastic methods. Analytical methods are
based on deterministic equations in order tomodel evolution
of a biological system. A set of diﬀerential equations with
multiple parameters is often used to model complex tumor
kinetics under various conditions. On the other hand,
stochastic methods use random number generators and
probability distributions to simulate evolution of the system
from a set of initial conditions and parameter values (also
known as in silico models). These methods are particularly
useful as they can take into account the high degree of
complexity and multifaceted nature of cellular proliferation,
communication, and interactions with reagents that cannot
be easily described by a set of equations.
Pros for modeling in cancer research are as follows.
(i) Modeling significantly reduces the time needed for an
outcome as compared to in vivo techniques; it also
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reduces the costs involved in the research and, very
importantly, reduces the risks, which, for example, in
a clinical trial are unavoidable.
(ii) Modeling allows the easy investigation of the “what
if?” scenarios; that is, models have predictive power.
(iii) Modeling allows for the quantitative assessment of
qualitative processes.
(iv) Because of the low costs involved, modeling allows
researchers with modest infrastructure to contribute
with valuable ideas to the field.
(v) Modeling enables to quantify and interpret experi-
mental results, including data obtained from clinical
trials.
Cons are as follows.
(i) It is very diﬃcult, if not impossible, to model the
entirety of a biological process.
(ii) There is always a compromise in a modeling process
as only a certain number of known biological pro-
cesses/parameters can be accounted for within the
model. This known compromise exists on top of the
unknown compromise represented by the obvious
omission of the unknown processes that happen in
the modeled biological system.
(iii) The results of an in silico model should be considered
clinically only after the credibility of the model has
been validated by several in vivo results.
Models can also allow for individualization of treatments.
It is therefore possible that in near future a patient can receive
individualized treatment based on their specific biologi-
cal/genetic parameters rather than undergoing a treatment
protocol that is based on population averages.
In this special issue we will explore the topic of com-
putational and mathematical modeling of tumor kinetics
and response to radiation and chemotherapy. The papers in
this issue have been contributed by eminent researchers and
research groups in the area of cancer modeling, radiation
biologymodeling, microdosimetry, andmany others. Several
papers oﬀer comprehensive reviews of current status of
cancer modeling in specific areas (e.g., hypoxia, glioblastoma
multiforme models, etc.). We trust that the readers will find
this issue both useful and practical as well as a good source of
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